Recent

% | $
Quotes you view appear here for quick access.

IntelliPharmaCeutics International Inc. Message Board

  • mogeycow1 mogeycow1 Nov 27, 2012 7:48 AM Flag

    NEWS NEWS NEWS Intellipharmaceutics Announces Results of Initial Phase I Clinical Trial of Controlled-Release Pregabalin and Product Updates

    TORONTO, Nov. 27, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced successful results of an initial Phase I clinical trial of a controlled-release pregabalin formulation. We also announced an update to the 2012 goals of our Rexista(TM) abuse-deterrent formulations for oxycodone, and an update to the development activities of our generic version of Focalin XR(R).
    Intellipharmaceutics successfully completed a Phase I clinical trial on our non-generic controlled-release formulation of pregabalin XR. This was the first bioavailability study of our controlled-release pregabalin versus Lyrica(R) (immediate release pregabalin) in 14 subjects. The results showed that our 150 mg pregabalin XR once-a-day dosage was comparable in bioavailability to Lyrica(R) 50 mg three-times-a-day dosage. Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury and fibromyalgia. A controlled-release version of pregabalin should reduce the number of doses patients take, potentially improving patient compliance, and therefore potentially improving clinical outcomes. We plan to initiate additional Phase I clinical trials in 2013. According to Wolters Kluwer Health, U.S. sales for the 12 months ending October 2012 for Lyrica(R) (pregabalin capsules) were approximately $2.0 billion. There is no controlled-release formulation on the market at this time.

    We are excited to announce the application of our Hypermatrix(TM) technology to another controlled- release product candidate," stated Dr. Isa Odidi, CEO and Co-Founder of Intellipharmaceutics. "Our formulation expertise continues to broaden the pipeline of Intellipharmaceutics' product candidates and expand our potential strategic commercial opportunities.
    Intellipharmaceutics' previously announced development goals for 2012 included the completion of clinical batch manufacturing of Rexista(TM) oxycodone, and the initiation of Phase I studies of Rexista(TM) oxycodone. We are pleased to announce our manufacture of batches under current Good Manufacturing Practices has been concluded, and we are now going into clinical trials with the manufactured batches. Preliminary Phase I data from this trial is expected in early 2013. According to Wolters Kluwer Health, U.S. sales for the 12 months ending October 2012 for OxyContin(R) were approximately $2.4 billion.
    "Our first proof-of-concept trial of Rexista(TM) oxycodone yielded bioavailability comparable to OxyContin(R). We plan to repeat these trials using our final formulation," commented Dr. Isa Odidi. "Addicts have found ways to abuse OxyContin(R). Our final Rexista(TM) oxycodone formula is designed to deter abuse from crushing, heating, dissolving and various extraction methods including dissolution in alcohol."

    We continue to await receipt of potential regulatory approval from the FDA for our generic version of Focalin XR(R). No additional information has been requested by the FDA in the last three months with regards to the abbreviated new drug application ("ANDA") that is currently under review. Upon receipt of regulatory approval, we may commence marketing our generic versions of 5, 10, 15 and 20 mg Focalin XR(R) with our commercialization partner Par Pharmaceutical, Inc. According to Wolters Kluwer Health, U.S. sales for the 12 months ending October 2012 for Focalin XR(R) were approximately $601 million.

    $7-$10 Soon

    BUY BUY BUY

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • FDA = $7-$10

      Sentiment: Strong Buy

    • GIDDY-UP

      Sentiment: Strong Buy

    • IPCI has NO SALES / NO PROFITS / NO APPROVALS in 14 years of business !!! Dr Reach & Grab needs the uninformed New Investors to Buy this stock to keep IPCI going !!! Its like a Nigerian Ponzi scheme instead of a company as NO GENERIC PILL has EVER been SOLD since they started IPCI !!! New potential investors need to ask the question will 30 MILLION $$$ worth of Stock DILUTION be good for my investment ?
      If you do the research into this company the TRUTH / FACTS are clear here .... its a Pump & Dump company based on Hype & ANDAs that never become SALES !!! Here is what is on IPCIs own website under Investor Relations / Press Releases for November 25th , 2011 !!!

      {TORONTO, Nov. 25, 2011 (GLOBE NEWSWIRE) -- (Nasdaq:IPCI) (TSX:I), a
      pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release
      and targeted-release oral solid dosage drugs, today announced that it has filed a preliminary short form base shelf prospectus
      with securities regulatory authorities in each of the provinces and territories of Canada, except Quebec, and filed a registration
      statement with the United States Securities and Exchange Commission on Form F-3. Once the shelf prospectus is cleared and
      the shelf registration statement becomes effective, these filings would, subject to securities regulatory requirements and
      limitations, provide for the potential offering of up to an aggregate of US$30 million of the Company's common shares,
      preference shares, warrants and subscription receipts, or any combination thereof, from time to time in one or more offerings
      over a 25-month period. This shelf prospectus is intended to give Intellipharmaceutics the flexibility to take advantage of
      financing opportunities when, and if, market conditions are favorable to the Company. The specific terms of such future
      offerings, if any, would be established, subject to the approval of the Company's Board of Directors, at the time of such offering
      and will be described in detail in a prospectus supplement filed at the time of any such offering.}

      Sentiment: Strong Sell

    • FDA SOON $7

      Sentiment: Strong Buy

    • IPCI has NO SALES / NO PROFITS / NO APPROVALS in 14 years of business !!! Dr Reach & Grab needs the uninformed New Investors to Buy this stock to keep IPCI going !!! Its like a Nigerian Ponzi scheme instead of a company as NO GENERIC PILL has EVER been SOLD since they started IPCI !!! New potential investors need to ask the question will 30 MILLION $$$ worth of Stock DILUTION be good for my investment ?
      If you do the research into this company the TRUTH / FACTS are clear here .... its a Pump & Dump company based on Hype & ANDAs that never become SALES !!! Here is what is on IPCIs own website under Investor Relations / Press Releases for November 25th , 2011 !!!

      {TORONTO, Nov. 25, 2011 (GLOBE NEWSWIRE) -- (Nasdaq:IPCI) (TSX:I), a
      pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release
      and targeted-release oral solid dosage drugs, today announced that it has filed a preliminary short form base shelf prospectus
      with securities regulatory authorities in each of the provinces and territories of Canada, except Quebec, and filed a registration
      statement with the United States Securities and Exchange Commission on Form F-3. Once the shelf prospectus is cleared and
      the shelf registration statement becomes effective, these filings would, subject to securities regulatory requirements and
      limitations, provide for the potential offering of up to an aggregate of US$30 million of the Company's common shares,
      preference shares, warrants and subscription receipts, or any combination thereof, from time to time in one or more offerings
      over a 25-month period. This shelf prospectus is intended to give Intellipharmaceutics the flexibility to take advantage of
      financing opportunities when, and if, market conditions are favorable to the Company. The specific terms of such future
      offerings, if any, would be established, subject to the approval of the Company's Board of Directors, at the time of such offering
      and will be described in detail in a prospectus supplement filed at the time of any such offering.}

      Sentiment: Strong Sell

    • IPCI has NO SALES / NO PROFITS / NO APPROVALS in 14 years of business !!! Dr Reach & Grab needs the uninformed New Investors to Buy this stock to keep IPCI going !!! Its like a Nigerian Ponzi scheme instead of a company as NO GENERIC PILL has EVER been SOLD since they started IPCI !!! New potential investors need to ask the question will 30 MILLION $$$ worth of Stock DILUTION be good for my investment ?
      If you do the research into this company the TRUTH / FACTS are clear here .... its a Pump & Dump company based on Hype & ANDAs that never become SALES !!! Here is what is on IPCIs own website under Investor Relations / Press Releases for November 25th , 2011 !!!

      {TORONTO, Nov. 25, 2011 (GLOBE NEWSWIRE) -- (Nasdaq:IPCI) (TSX:I), a
      pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release
      and targeted-release oral solid dosage drugs, today announced that it has filed a preliminary short form base shelf prospectus
      with securities regulatory authorities in each of the provinces and territories of Canada, except Quebec, and filed a registration
      statement with the United States Securities and Exchange Commission on Form F-3. Once the shelf prospectus is cleared and
      the shelf registration statement becomes effective, these filings would, subject to securities regulatory requirements and
      limitations, provide for the potential offering of up to an aggregate of US$30 million of the Company's common shares,
      preference shares, warrants and subscription receipts, or any combination thereof, from time to time in one or more offerings
      over a 25-month period. This shelf prospectus is intended to give Intellipharmaceutics the flexibility to take advantage of
      financing opportunities when, and if, market conditions are favorable to the Company. The specific terms of such future
      offerings, if any, would be established, subject to the approval of the Company's Board of Directors, at the time of such offering
      and will be described in detail in a prospectus supplement filed at the time of any such offering.}

      Sentiment: Strong Sell

    • IPCI has NO SALES / NO PROFITS / NO APPROVALS in 14 years of business !!! Dr Reach & Grab needs the uninformed New Investors to Buy this stock to keep IPCI going !!! Its like a Nigerian Ponzi scheme instead of a company as NO GENERIC PILL has EVER been SOLD since they started IPCI !!! New potential investors need to ask the question will 30 MILLION $$$ worth of Stock DILUTION be good for my investment ?
      If you do the research into this company the TRUTH / FACTS are clear here .... its a Pump & Dump company based on Hype & ANDAs that never become SALES !!! Here is what is on IPCIs own website under Investor Relations / Press Releases for November 25th , 2011 !!!

      {TORONTO, Nov. 25, 2011 (GLOBE NEWSWIRE) -- (Nasdaq:IPCI) (TSX:I), a
      pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release
      and targeted-release oral solid dosage drugs, today announced that it has filed a preliminary short form base shelf prospectus
      with securities regulatory authorities in each of the provinces and territories of Canada, except Quebec, and filed a registration
      statement with the United States Securities and Exchange Commission on Form F-3. Once the shelf prospectus is cleared and
      the shelf registration statement becomes effective, these filings would, subject to securities regulatory requirements and
      limitations, provide for the potential offering of up to an aggregate of US$30 million of the Company's common shares,
      preference shares, warrants and subscription receipts, or any combination thereof, from time to time in one or more offerings
      over a 25-month period. This shelf prospectus is intended to give Intellipharmaceutics the flexibility to take advantage of
      financing opportunities when, and if, market conditions are favorable to the Company. The specific terms of such future
      offerings, if any, would be established, subject to the approval of the Company's Board of Directors, at the time of such offering
      and will be described in detail in a prospectus supplement filed at the time of any such offering.}

      Sentiment: Strong Sell

    • Phase I trial doesn't mean anything! At the rate IPCI works, we'll be looking at submitting an application to the FDA in ~10 years! Absolutely nothing to get excited about until an actual approval... not just a bunch of bozos saying approval imminent for 2 years!

    • IPCI has NO SALES / NO PROFITS / NO APPROVALS in 14 years of business !!! Dr Reach & Grab needs the uninformed New Investors to Buy this stock to keep IPCI going !!! Its like a Nigerian Ponzi scheme instead of a company as NO GENERIC PILL has EVER been SOLD since they started IPCI !!! New potential investors need to ask the question will 30 MILLION $$$ worth of Stock DILUTION be good for my investment ?
      If you do the research into this company the TRUTH / FACTS are clear here .... its a Pump & Dump company based on Hype & ANDAs that never become SALES !!! Here is what is on IPCIs own website under Investor Relations / Press Releases for November 25th , 2011 !!!

      {TORONTO, Nov. 25, 2011 (GLOBE NEWSWIRE) -- (Nasdaq:IPCI) (TSX:I), a
      pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release
      and targeted-release oral solid dosage drugs, today announced that it has filed a preliminary short form base shelf prospectus
      with securities regulatory authorities in each of the provinces and territories of Canada, except Quebec, and filed a registration
      statement with the United States Securities and Exchange Commission on Form F-3. Once the shelf prospectus is cleared and
      the shelf registration statement becomes effective, these filings would, subject to securities regulatory requirements and
      limitations, provide for the potential offering of up to an aggregate of US$30 million of the Company's common shares,
      preference shares, warrants and subscription receipts, or any combination thereof, from time to time in one or more offerings
      over a 25-month period. This shelf prospectus is intended to give Intellipharmaceutics the flexibility to take advantage of
      financing opportunities when, and if, market conditions are favorable to the Company. The specific terms of such future
      offerings, if any, would be established, subject to the approval of the Company's Board of Directors, at the time of such offering
      and will be described in detail in a prospectus supplement filed at the time of any such offering.}

      Sentiment: Strong Sell

    • This is going to lead us to 3 bucks again, just in time.Oeffff.What a great news!

      Sentiment: Strong Buy

    • View More Messages
 
IPCI
2.210.00(0.00%)Feb 9 3:59 PMEST